***Background.*** *Enterobacteriaceae* play a significant role in LRT infections in at risk patients, especially in the healthcare associated environment. Treatment options are increasingly limited due to increased resistance to cephalosporins and other antimicrobials, thus warranting careful monitoring of resistance trends. The purpose of this study was to determine the *in vitro* activity of Tigecycline and other key antibiotics against LRT isolates of *Enterobacteriaceae* obtained from patients in North American and European hospitals.

***Methods.*** From 2009-2013 8,361 *Enterobacteriaceae* from LRT specimens were obtained from geographically distributed sites as part of the multi-year Tigecycline Evaluation Surveillance Trial (TEST). MICs were determined by the local laboratory using supplied microdilution panels and interpreted according to CLSI guidelines.

***Results.*** 

                 Percent Susceptible                                                           
  -------------- --------------------- ------ ------ ------ ------ ------ ------ ------ ------ ------
  Drug n =       440                   601    576    1472   537    1100   943    1683   390    619
  Amikacin       98.0                  97.5   97.9   97.4   98.3   95.8   98.3   98.5   98.7   99.0
  Cefepime       92.7                  91.4   93.6   90.0   92.0   86.9   93.4   88.5   90.8   90.6
  Ceftriaxone    73.9                  72.1   72.1   67.7   75.6   69.7   80.3   71.0   78.2   71.1
  Levofloxacin   83.4                  84.2   86.6   82.1   84.4   81.4   87.6   83.6   85.4   83.4
  Meropenem      96.4                  97.2   96.2   98.7   97.8   96.5   97.3   97.0   96.2   97.7
  Pip-Tazo^b^    83.4                  80.4   85.2   78.9   83.6   79.3   86.2   83.1   88.2   85.0
  Tigecycline    98.0                  94.7   96.4   96.4   96.8   97.7   96.3   97.0   96.2   97.0

^a^NA: North America, EU: Europe; Pip-Tazo = piperacillin/tazobactam

***Conclusion.*** Tigecycline, amikacin and meropenem consistently demonstrated the highest % susceptibility (\> 95%) against LRT isolates of *Enterobacteriaceae* regardless of study year or geographic region. Ceftriaxone was less active against European isolates than against North American isolates overall irrespective of study year possibly due to extended-spectrum β-lactamase prevalence in Europe vs North America. Levofloxacin susceptibility was stable in the mid-80% range over all years. Tigecycline is not indicated for lower respiratory tract infections caused by *Enterobacteriaceae.*
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